| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/26/2004 | US20040039200 1,2,3,4,10,10a-hexahydropyrazino(1,2-a)indole derivatives useful for treating disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders, and diabetes |
| 02/26/2004 | US20040039198 Administering to a mammal an aromatic and heteroacromatic substituted imidazole compound to treat diseases: renal disease, wound healing, ucler, ocular disorder, diabetic nephropathy, atherosclerosis, fibrosis, ALzheimer's disease |
| 02/26/2004 | US20040039196 (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors |
| 02/26/2004 | US20040039184 Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof |
| 02/26/2004 | US20040039160 Comprises therapeutic agent, oligopeptide having an isoleucine residue, stabilizing group, and, optionally, a linker group; prodrug is cleavable by an enzyme associated with target cell; antitumor agents |
| 02/26/2004 | US20040039061 Suppress expression and induction of inflammatory cytokines, cell adhesion molecule gene and virus and suppressors for nuclear factor kappa beta (nf-kb) |
| 02/26/2004 | US20040039060 Capable of chelating both of the two divalent metal ions at the same time, a prodrug or a solvate |
| 02/26/2004 | US20040039055 Ameliorate the negative side effects of a serum concentration of a drug higher than that used in normal clinical practice |
| 02/26/2004 | US20040039054 Use of L-carnitine and derivatives for reducing ceramide levels and potentiating antiretroviral drugs |
| 02/26/2004 | US20040039050 Formulating phenanthro(1,2-b)-furan compound for eliminating hyperammonemia in the brain tissue for treating early stage Alzheimer's disease |
| 02/26/2004 | US20040039046 Scyphostatin analogues as SMase inhibitors |
| 02/26/2004 | US20040039045 (2-azabicyclo(2.2.1)hept-7yl)methylcarbamate derivatives are useful for treating schizophrenia, Alzheimer's disease, neurodegenerative disorders, Parkinson's disease, Tourette's syndrome, age related memory loss and withdrawal symptoms |
| 02/26/2004 | US20040039040 Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient |
| 02/26/2004 | US20040039038 Biaromatic compound activators of PPARy-type receptors |
| 02/26/2004 | US20040039031 A combination of an antidiabetic biguanide and an antidiabetic sulfonamide, at low doses, in combination or as a mixture with inert excipient(s) |
| 02/26/2004 | US20040039029 Thiazolyl urea compounds and methods of uses |
| 02/26/2004 | US20040039025 Substituted hydrazine derivatives |
| 02/26/2004 | US20040039024 Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them |
| 02/26/2004 | US20040039017 Heterocyclic amines such as 2-(3-(4-Chloro-3-trifluoromethyl-benzylamino)prop-1-ylamino)-1H-quinolin-4 -one, used as G-protein coupled receptor inhibitors, for prophylaxis of cardiovascular disorders, schizophrenia or diabetes |
| 02/26/2004 | US20040039015 Estrogen Receptor-beta ligands |
| 02/26/2004 | US20040039007 Nitrogen compounds such as (6-(3-Methylaminopropyl)-2-(2-tri-fluoromethylphenyl)pyrimidin-4-yl)-(1H -pyrazolo(3,4-b)pyridin-3-yl)-amine, use as glycogen synthase kinase-3 (GSK-3) antagonists |
| 02/26/2004 | US20040039006 (2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use |
| 02/26/2004 | US20040039004 Nitrogen compounds such as 4-(5-amino-7-phenethyl-7H-pyrazolo (4,3-e)(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-phenol, used as adenosine receptor antagonists, for prophylaxis of nervous, cardiovascular, respiratory, urogenital and immune disorders |
| 02/26/2004 | US20040039001 2-guanidino-4-aryl-quinazoline |
| 02/26/2004 | US20040038995 Inhibitors of both KDR an FGFR kinases and are selective against LCK; for treatment of solid tumors, in particular breast, colon, lung and prostate tumors. |
| 02/26/2004 | US20040038991 Imidazolyl-cyclic acetals |
| 02/26/2004 | US20040038978 Chemical compounds |
| 02/26/2004 | US20040038977 Treating arthritis, pain and cancer |
| 02/26/2004 | US20040038976 S,N-diarylsulfonamide derivatives; treating inflammatory diseases such as Celiac's disease, Crohn's disease or colitis. |
| 02/26/2004 | US20040038964 Imidazole derivatives as raf kinase inhibitors |
| 02/26/2004 | US20040038963 5,5-Difluoro-3(S)-(pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-(1, 8)-naphthyridin-2-yl)-nonanoic acid; inhibition of bone resorption, restenosis, angiogenesis, retinopathy, macular degeneration, arthritis, metastatic tumor growth, etc. |
| 02/26/2004 | US20040038962 Treatment of nocturnal enuresis, nocturia, polyuria resulting from central diabetes insipidus, urinary incontinence or bleeding disorders such a hemophilia |
| 02/26/2004 | US20040038952 Combination of a bile acid and a bioflavonoid; also for treating eye disorders and premenstrual symptoms. |
| 02/26/2004 | US20040038949 Inhibitors of the enzyme CYP24; useful for treating cell-proliferative disorders and for promoting cell differentiation. |
| 02/26/2004 | US20040038945 Administering pyridoxal-5'-phosphate, pyridoxamine, pyridoxal, or a 3-acylated pyridoxal analogue with a therapeutic cardiovascular compound. |
| 02/26/2004 | US20040038943 Indole and benzimidazole 15-lipoxygenase inhibitors |
| 02/26/2004 | US20040038942 Medicament for treatment of bone marrow suppression, for treatment of infectious diseases and for increasing the number of leukocytes |
| 02/26/2004 | US20040038938 Increasing the survival or growth of motoneurons; treating diseases such as amyotrophic lateral sclerosis, progressive spinal muscular atrophy, infantile muscular atrophy and primary lateral sclerosis. |
| 02/26/2004 | US20040038932 Antithrombotic compositions |
| 02/26/2004 | US20040038929 Drugs against articular failure |
| 02/26/2004 | US20040038928 N-pyrazole A2A receptor agonists |
| 02/26/2004 | US20040038907 For healing wounds/tissue repair |
| 02/26/2004 | US20040038905 Anticancer agents |
| 02/26/2004 | US20040038900 For therapy of diabetes and other insulin-requiring states, hypoglycemia |
| 02/26/2004 | US20040038893 Prevention and reduction of blood loss |
| 02/26/2004 | US20040038887 Copolymers for suppression of autoimmune diseases, and methods of use |
| 02/26/2004 | US20040038879 For therapy and prophylaxis of infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, pain, cancers, anorexia, bulimia, asthma, Parkinson's disease, acute heart failure |
| 02/26/2004 | US20040038871 Attaching a linker to an amino group of the drug, the linker including an aldehyde or ketone carbonyl group, and forming an oxime by reaction of the carbonyl group with an O-alkylhydroxylamine derivative of the peptide |
| 02/26/2004 | US20040038863 Therapy of growth failure in an individual, comprising administering to the individual an aromatase inhibitor |
| 02/26/2004 | US20040038857 Treating the cell with a cholinergic agonist in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from the cell, wherein the cell is a macrophage |
| 02/26/2004 | US20040038399 For preventing gene transcription/expression; for inducing nuclease stability, hybridization to complementary RNA sequences, permeability to oligonucleotides into cells, RNase cleavage, and blocking ribosome translocation |
| 02/26/2004 | US20040038370 Claudin polypeptides |
| 02/26/2004 | US20040038362 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 02/26/2004 | US20040038293 Antibodies to human cd154 |
| 02/26/2004 | US20040038274 Gapped 2' modified oligonucleotides |
| 02/26/2004 | US20040038265 Using low density lipoprotein related proteins (LRP) to diagnose, treat and prevent paget's, osteoporosis, cirrhosis and rickets |
| 02/26/2004 | US20040038257 Therapeutic peptidase for diagnosis, treatment and prevention of cancer and nervous system disorders |
| 02/26/2004 | US20040038243 P53-dependent apoptosis-associated protein and method of screening apoptosis controlling agent |
| 02/26/2004 | US20040038236 Mutation associated with epilepsy |
| 02/26/2004 | US20040038223 Comprise polypeptide for diagnosis, prevention and treatment of cardiomyopathy, atherosclerosis, hypertension, cancer, diabetes and nervous system disorders |
| 02/26/2004 | US20040038215 Oligonucleotide tagged nucleoside triphosphates (OTNTPs) for genetic analysis |
| 02/26/2004 | US20040037901 Rosmarinus extracts for inhibiting/treating skin aging |
| 02/26/2004 | US20040037897 Treatment of drug resistant organisms |
| 02/26/2004 | US20040037896 Intravenous injection of lignocaine (lidocaine) or a salt, ester or metabolite for use in initiating the natural capacity to regenerate collateral blood vessels; cerebral arterial occlusions; artherosclerosis; angina pectoris |
| 02/26/2004 | US20040037829 For immunoregulation and/or treatment of inflammation; muteins |
| 02/26/2004 | US20040037824 Epidermal growth factors (ErbB2); gene expression inhibition; anticancer agents |
| 02/26/2004 | US20040037823 Epidermal growth factors (ErbB2); comprises doxorubicin; gene expression inhibition; anticancer agents |
| 02/26/2004 | US20040037821 For expression of erythropoietin; genetic translocation; zinc finger motifs |
| 02/26/2004 | US20040037808 Methods for modulating T cell responses by manipulating a commom cytokine receptor gamma-chain |
| 02/26/2004 | DE20318634U1 Topical compositions for preventing or treating rhinitis, comprising sympathomimetic agent with vasoconstrictive and/or mucosal swelling reducing action and glycosaminoglycan to reduce side-effects |
| 02/26/2004 | DE10232020A1 Neurorezeptoraktive Heteroarencarboxamide Neuroreceptor Active Heteroarencarboxamide |
| 02/26/2004 | CA2497347A1 R(+)-2-amino-3-hydroxypropanoic acid derivatives with glycinergic action |
| 02/26/2004 | CA2496419A1 Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof |
| 02/26/2004 | CA2495452A1 Use of reboxetine for the treatment of hot flashes |
| 02/26/2004 | CA2495409A1 Diaryl compounds as monoamine reuptake inhibitors |
| 02/26/2004 | CA2495383A1 Fused benzene derivative and use |
| 02/26/2004 | CA2495185A1 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| 02/26/2004 | CA2495184A1 Thrombopoietin receptor activators and process for their production |
| 02/26/2004 | CA2495068A1 Use of nf-kappa b inhibitors for the treatment of mastitis |
| 02/26/2004 | CA2493246A1 Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists |
| 02/25/2004 | EP1391516A1 Von willebrand factor (vwf)-cleaving enzyme |
| 02/25/2004 | EP1391514A1 Pharmaceutical composition for treatment of angiogenesis-dependent conditions |
| 02/25/2004 | EP1391512A1 Polypeptide serving as angiogenic marker and dna thereof |
| 02/25/2004 | EP1391461A1 Bicyclic lactam inhibitors of interleukin-1-beta converting enzyme |
| 02/25/2004 | EP1391458A2 Novel method for producing 5-aryloxymethyl-2-oxazolidinones |
| 02/25/2004 | EP1391457A1 Substituted 2-Phenylbenzimidazoles and their use as PARP inhibitors |
| 02/25/2004 | EP1391456A1 2-iminoimidazole derivative (2) |
| 02/25/2004 | EP1391453A1 Pyroglutamic acid salt of amlodipine |
| 02/25/2004 | EP1391451A1 2-iminopyrrolidine derivates |
| 02/25/2004 | EP1391426A1 Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate |
| 02/25/2004 | EP1391204A1 Nerve cell survival promoters containing cyclic phosphatidic acid derivative |
| 02/25/2004 | EP1391199A1 Carboxylic acid derivatives and drugs containing the same as the active ingredient |
| 02/25/2004 | EP1391198A1 Novel sphingolipid synthesis inhibitor |
| 02/25/2004 | EP1390740A1 Methods and formulations for increasing the affinity of a 1? adenosine receptor ligands for the a 1? adenosine receptor |
| 02/25/2004 | EP1390534A2 Methods for diagnosis and treatment of inflammatory bowel disease |
| 02/25/2004 | EP1390497A2 Human cdnas and proteins and uses thereof |
| 02/25/2004 | EP1390496A2 Glutamate receptor modulatory proteins and nucleic acids encoding them |
| 02/25/2004 | EP1390481A2 RECOMBINANT EXPRESSION OF hHBV REVERSE TRANSCRIPTASE (RT) |
| 02/25/2004 | EP1390478A1 Compounds capable of modulating the activity and stimulating the production of a catalytic antibody |
| 02/25/2004 | EP1390406A2 Method of modulating the proliferation of medullary thyroid carcinoma cells |